{
    "clinical_study": {
        "@rank": "99122", 
        "acronym": "SORT OUT VII", 
        "arm_group": [
            {
                "arm_group_label": "ORSIRO stent", 
                "arm_group_type": "Active Comparator", 
                "description": "ORSIRO stent group"
            }, 
            {
                "arm_group_label": "NOBORI stent", 
                "arm_group_type": "Active Comparator", 
                "description": "NOBORI stent group"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is\n      to compare the safety and efficacy of the sirolimus eluting ORSIRO stent and the\n      biolimus-eluting NOBORI stent in a population-based setting, using registry detection of\n      clinically driven events"
        }, 
        "brief_title": "Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Ischemic Heart Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "SORT OUT VII is a randomized, multicenter, all-comer, two-arm, non-inferiority trial\n      comparing the sirolimus eluting ORSIRO stent to the biolimus-eluting NOBORI stent in\n      treating atherosclerotic coronary artery lesions.\n\n      Primary Endpoint:\n\n      Target lesion failure within 12 months of stent implantation (combination of  cardiac death,\n      myocardial infarction (not index procedure related) not related to other than index lesion\n      or target lesion revascularization).\n\n      Secondary Endpoints:\n\n      Individual components of the primary end point comprised the secondary end points and stent\n      thrombosis rate according to the Academic Research Consortium definition (see protocol for\n      further specification of secondary endpoints).\n\n      Clinically driven event detection will be used to avoid study-induced reinterventions. Data\n      on mortality, hospital admission, coronary angiography, repeat percutaneous coronary\n      intervention, and coronary bypass surgery will be obtained for all randomly allocated\n      patients from the following national Danish administrative and healthcare registries: the\n      Civil Registration System; the Western Denmark Heart Registry; the Danish National Registry\n      of Patients, which maintains records on all hospitalizations in Denmark; and the Danish\n      Registry of Causes of Death\n\n      Inclusion criteria:\n\n      at least 18 years old chronic stable coronary artery disease or acute coronary syndromes at\n      least one coronary artery lesion with more than 50% diameter stenosis requiring treatment\n      with a drug-eluting stent\n\n      Exclusion criteria:\n\n      life expectancy of less than one year allergy to aspirin, clopidogrel, sirolimus, or\n      biolimus participation in another randomized trial nability to provide written informed\n      consent"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 18 years or over with chronic stable coronary artery disease or acute\n             coronary syndromes, and at least one coronary artery lesion with more than 50%\n             diameter stenosis, requiring treatment with a drug-eluting stent. There are no\n             restrictions on number of treated lesions, number of treated vessels, or lesion\n             length.\n\n        Exclusion Criteria:\n\n          -  Exclusion criteria are life expectancy of less than one year; an allergy to aspirin,\n             clopidogrel, ticagrelor, prasugral, sirolimus, or biolimus; participation in another\n             randomized trial; or inability to provide written informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "2314", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879358", 
            "org_study_id": "SORT OUT VII", 
            "secondary_id": "OUH"
        }, 
        "intervention": {
            "arm_group_label": [
                "ORSIRO stent", 
                "NOBORI stent"
            ], 
            "intervention_name": "Drug-eluting stent", 
            "intervention_type": "Device", 
            "other_name": [
                "ORSIRO sirolimus-eluting stent", 
                "NOBORI biolimus-eluting stent"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug-eluting stent", 
            "Safety", 
            "Efficacy"
        ], 
        "lastchanged_date": "June 14, 2013", 
        "link": {
            "description": "SORT OUT IV with same clinically event driven methodology", 
            "url": "http://www.ncbi.nlm.nih.gov/pubmed/22308301"
        }, 
        "location": {
            "contact": {
                "email": "okkels@dadlnet.dk", 
                "last_name": "Lisette Okkels Jensen, MD DMSci PhD", 
                "phone": "004565412620"
            }, 
            "contact_backup": {
                "email": "per.thayssen@ouh.regionsyddanmark.dk", 
                "last_name": "Per Thayssen, MD DMSci", 
                "phone": "004565412691"
            }, 
            "facility": {
                "address": {
                    "city": "Odense", 
                    "country": "Denmark", 
                    "zip": "5000"
                }, 
                "name": "Odense University Hospital"
            }, 
            "investigator": {
                "last_name": "Lisette Okkels Jensen, MD DMSci PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Comparison of a Sirolimus Eluting ORSIRO Stent With a Biolimus-eluting NOBORI Stent in Patients Treated With Percutaneous Coronary Intervention", 
        "overall_contact": {
            "email": "okkels@dadlnet.dk", 
            "last_name": "Lisette Okkels Jensen, MD DMSci PhD", 
            "phone": "004565412620"
        }, 
        "overall_contact_backup": {
            "email": "per.thayssen@ouh.regionsyddanmark.dk", 
            "last_name": "Per Thayssen, MD DMSci", 
            "phone": "004565412681"
        }, 
        "overall_official": {
            "affiliation": "Aarhus University Hospital", 
            "last_name": "Jens F Lassen, MD DMSci", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: The Danish National Committee on Biomedical Research Ethics", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Target lesion failure within 12 months of stent implantation (combination of  cardiac death, myocardial infarction (not index procedure related) not related to other than index lesion or target lesion revascularization)", 
            "measure": "Cardiac death, myocardial infarction or target lesion revascularization", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879358"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Odense University Hospital", 
            "investigator_full_name": "Lisette Okkels Jensen", 
            "investigator_title": "MD DMSci PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Cardiac mortality Myocardial infarction Target lesion revascularization Target vessel revascularization All cause mortality Stent thrombosis rate according to the Academic Research Consortium definition Secondary endpoints will be assessed after 1 year, 2 years, 3 years, 4 years and 5 years.", 
            "measure": "Cardiac death, myocardial infarction, target lesion revascularization, target vessel revascularization, all cause mortality, stent thrombosis", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "Odense University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Odense University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}